Federal contract award
75N93021C00006
MHC, KIR AND FCR DEVELOPMENT
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST NO FEE |
| Obligations | $6.4M |
| Current contract value | $6.4M |
| Potential contract value / ceiling | $12.9M |
| Start date | Jun 1, 2021 |
| Current end date | May 31, 2028 |
| Potential end date | May 31, 2028 |
| Latest award activity | Aug 7, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 14 of 14 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 7, 2026 | P00013 | $-26.3K | EO 14398 TO ADMINISTRATE DE-OBLIGATE UNEXPENDED AND EXPIRING FISCAL YEAR 2021 FUNDING IN ACCORDANCE WITH 31 U.S.C. SECTION 1552 (A), IN PREPARATION FOR SEPTEMBER 30, 2026, CLOSING OF THE PERIOD OF AVAILABILITY OF THESE FISCAL YEAR FUNDS. |
| May 14, 2026 | P00012 | $1.1M | THE PRIMARY PURPOSE OF THIS CONTRACT IS TO DISCOVER NEW NHP MHC CLASS I, MHC CLASS II, KIR, AND FCR GENES, LOCI, AND ALLELES; DEVELOP GENOTYPING TECHNOLOGIES THAT WILL REMAIN FREELY ACCESSIBLE TO THE NHP RESEARCH COMMUNITY; PROVIDE ALL SEQUENCES GENE |
| May 13, 2025 | P00011 | $325.5K | EOI::EO:RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING NHP MHC AND KIR ALLELE DISCOVERY AND TYPING TECHNOLOGY DEVELOPMENT |
| Sep 11, 2024 | P00010 | $349.6K | THE PRIMARY PURPOSE OF THIS CONTRACT IS TO DISCOVER NEW NHP MHC CLASS I, MHC CLASS II, KIR, AND FCR GENES, LOCI, AND ALLELES; DEVELOP GENOTYPING TECHNOLOGIES THAT WILL REMAIN FREELY ACCESSIBLE TO THE NHP RESEARCH COMMUNITY; PROVIDE ALL SEQUENCES GE |
| Jul 12, 2024 | P00009 | $133.9K | THE PRIMARY PURPOSE OF THIS CONTRACT IS TO DISCOVER NEW NHP MHC CLASS I, MHC CLASS II, KIR, AND FCR GENES, LOCI, AND ALLELES; DEVELOP GENOTYPING TECHNOLOGIES THAT WILL REMAIN FREELY ACCESSIBLE TO THE NHP RESEARCH COMMUNITY; PROVIDE ALL SEQUENCES GE |
| May 24, 2024 | P00008 | $1.1M | THE PRIMARY PURPOSE OF THIS CONTRACT IS TO DISCOVER NEW NHP MHC CLASS I, MHC CLASS II, KIR, AND FCR GENES, LOCI, AND ALLELES; DEVELOP GENOTYPING TECHNOLOGIES THAT WILL REMAIN FREELY ACCESSIBLE TO THE NHP RESEARCH COMMUNITY; PROVIDE ALL SEQUENCES GE |
| Jun 9, 2023 | P00007 | $90.1K | THE PRIMARY PURPOSE OF THIS CONTRACT IS TO DISCOVER NEW NHP MHC CLASS I, MHC CLASS II, KIR, AND FCR GENES, LOCI, AND ALLELES; DEVELOP GENOTYPING TECHNOLOGIES THAT WILL REMAIN FREELY ACCESSIBLE TO THE NHP RESEARCH COMMUNITY; PROVIDE ALL SEQUENCES GE |
| May 23, 2023 | P00006 | $1.1M | THE PRIMARY PURPOSE OF THIS CONTRACT IS TO DISCOVER NEW NHP MHC CLASS I, MHC CLASS II, KIR, AND FCR GENES, LOCI, AND ALLELES DEVELOP GENOTYPING TECHNOLOGIES THAT WILL REMAIN FREELY ACCESSIBLE TO THE NHP RESEARCH COMMUNITY PROVIDE ALL SEQUENCES GE |
| May 19, 2022 | P00004 | $1.1M | THE PRIMARY PURPOSE OF THIS CONTRACT IS TO DISCOVER NEW NHP MHC CLASS I, MHC CLASS II, KIR, AND FCR GENES, LOCI, AND ALLELES; DEVELOP GENOTYPING TECHNOLOGIES THAT WILL REMAIN FREELY ACCESSIBLE TO THE NHP RESEARCH COMMUNITY; PROVIDE ALL SEQUENCES GE |
| May 19, 2022 | P00005 | $0 | THE PRIMARY PURPOSE OF THIS CONTRACT IS TO DISCOVER NEW NHP MHC CLASS I, MHC CLASS II, KIR, AND FCR GENES, LOCI, AND ALLELES; DEVELOP GENOTYPING TECHNOLOGIES THAT WILL REMAIN FREELY ACCESSIBLE TO THE NHP RESEARCH COMMUNITY; PROVIDE ALL SEQUENCES GE |
| Feb 24, 2022 | P00003 | $0 | THE PRIMARY PURPOSE OF THIS CONTRACT IS TO DISCOVER NEW NHP MHC CLASS I, MHC CLASS II, KIR, AND FCR GENES, LOCI, AND ALLELES; DEVELOP GENOTYPING TECHNOLOGIES THAT WILL REMAIN FREELY ACCESSIBLE TO THE NHP RESEARCH COMMUNITY; PROVIDE ALL SEQUENCES GE |
| Dec 21, 2021 | P00002 | $0 | DEVELOP GENO TYPING TECHNOLOGIES |
| Oct 12, 2021 | P00001 | $0 | EO14042 ENSURING ADEQUATE COVID SAFETY PROTOCOLS FOR FEDERAL CONTRACTORS |
| Mar 8, 2021 | 0 | $1.1M | MHC, KIR AND FCR DEVELOPMENT |
Estimated positioning window
May 31, 2027 – Nov 30, 2027
Recompete signal: . Rule-based research score; positioning dates are estimates.
70/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 70/100. Available recorded signals: 65 points.
- Contract end 2028-05-31 (577 days from calculation)
- +25 points
- 157 historical awards in this buyer and category group
- +15 points
- 14 recorded award transactions
- +10 points
- Latest award action: 2026-08-07
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.